Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.

Hiroshi SasakiKenta MikiKojiro TashiroKeiichiro MoriFumihiko UrabeWataru FukuokayaTakahiro KimuraShun SatoHiroyuki TakahashiManabu AokiShin Egawa

Published in: Andrology (2021)

The recovery patterns of hormonal profiles after short-term (12 weeks) neoadjuvant ADT differ between GnRH antagonists and GnRH agonists. The choice between these drugs matters and may have a clinical impact depending on the primary objective of ADT.

Keyphrases

rectal cancer
locally advanced
randomized controlled trial
stem cells
type diabetes
decision making
gestational age
radiation therapy
squamous cell carcinoma
mesenchymal stem cells
bone marrow
placebo controlled